An official website of the United States government
Hepatitis B Surface Antigen Screening Among Pregnant Women and Care of Infants of Hepatitis B Surface Antigen–Positive Mothers — Guam, 2014
Weekly / May 19, 2017 / 66(19);506–508
Winston E. Abara, MD, PhD1,2; Susan Cha, PhD1,3; Tasneem Malik, MSN, MPH3; Mia S. DeSimone, MD4,5; Bernadette Schumann, MPA6; Esther Mallada6; Michael Klemme7; Vince Aguon, MPA6; Anne Marie Santos6; Melissa Collier, MD2; Mary Kamb, MD3 (View author affiliations)
View suggested citationSummary
What is already known about this topic?
Hepatitis B virus (HBV) infection is endemic in the U.S. territory of Guam, and perinatal transmission is a major mode of transmission. The Advisory Committee on Immunization Practices recommends that all pregnant women be screened for hepatitis B surface antigen (HBsAg) in each pregnancy and that infants of HBsAg-positive women receive postexposure prophylaxis (PEP) with hepatitis B vaccine and hepatitis B immune globulin (HBIG) within 12 hours of birth to reduce the risk for perinatal HBV transmission.
What is added by this report?
In a hospital-based random sample of women with a live birth during 2014 in Guam, HBsAg seroprevalence (2.0%) was approximately 13 times higher than that among U.S.-born Pacific Islander and Asian women (0.14%) and approximately twice the overall U.S. maternal prevalence estimate (0.9%). Approximately 90% of HBsAg-positive women were born before introduction of universal infant hepatitis B vaccination. Among women who had at least one prenatal care visit, 98% received prenatal HBsAg screening, compared with 85% of women who did not receive prenatal care. All infants of HBsAg-positive women received hepatitis B vaccine and all but one infant received HBIG.
What are the implications for public health practice?
Prenatal HBSAg screening facilitates prompt identification of HBsAg-positive pregnant women and mitigates the risk for perinatal HBV transmission. Timely administration of PEP to infants of HBsAg-positive women is important to prevent perinatal HBV transmission.
Hepatitis B virus (HBV) infection is endemic among adults in the U.S. territory of Guam (1,2). Perinatal HBV transmission, which occurs at birth from an infected mother to her newborn infant, is a major mode of HBV transmission and maintains HBV endemicity (3). Approximately 90% of HBV-infected infants will develop chronic HBV infection, and approximately 25% of those will die prematurely from liver failure or hepatocellular carcinoma (4,5). Since 1988, the Advisory Committee on Immunization Practices has recommended that all pregnant women be screened for hepatitis B surface antigen (HBsAg), an indicator of HBV infection, and that infants of women who screen positive (HBsAg-positive women) receive postexposure prophylaxis (PEP) (hepatitis B vaccine and hepatitis B immunoglobulin [HBIG]). When received within 12 hours of birth, PEP is 85%–95% effective in preventing perinatal HBV transmission (5,6). Hepatitis B vaccine provides long-term active immunity to HBV infection and HBIG provides short-term passive immunity to HBV infection until the infant responds to the vaccine (5). Hepatitis B vaccine was introduced into the routine universal infant vaccination schedule in Guam in 1988 (1).
Data for this analysis were obtained from the medical records of pregnant women who delivered live-born infants at Guam Memorial Hospital in 2014. This hospital is the largest delivery hospital in Guam and accounted for approximately 73% of all recorded births in 2014. Among 2,478 live-born infants delivered at this hospital during 2014, a sample of 971 (39%) was randomly selected. After excluding one infant from each of the five sets of twins in the selected sample, the final analytical sample consisted of 966 mother-infant pairs. Prenatal medical records of mothers of all 966 infants and vaccination records of infants of HBsAg-positive women were reviewed. Maternal demographic and clinical care data as well as information on the administration of hepatitis B vaccine and HBIG to infants of HBsAg-positive women were collected using a standardized chart abstraction tool. Descriptive analyses and frequencies were performed to calculate the prevalence of prenatal HBsAg screening, HBsAg positivity, demographic characteristics, prenatal care among pregnant women and the administration of hepatitis B vaccination and HBIG to infants of HBsAg-positive women. Receipt of prenatal care was defined as having ≥1 prenatal care visit before admission for delivery, and prenatal HBsAg screening was defined as documentation of testing for HBsAg at any time before birth, including during the delivery admission.
Among the 966 women in this sample, 752 (78%) were Pacific Islanders, 197 (21%) were Asian, 11 (1%) were white, and two (<1%) were Hispanic (Table). The mean and median age at delivery was 27 years (range = 15–45 years); 542 (56.1%) women were aged >25 years at delivery. Information on prenatal HBsAg screening was available for 936 (97%) women, 905 (97%) of whom received prenatal HBsAg screening. Overall, 857 (89%) women received prenatal care; among this group, prenatal HBsAg screening information was available for 834 (97%) women, 818 (98%) of whom were screened for HBsAg. Among the 106 (11%) women who did not receive prenatal care, prenatal HBsAg screening data were available for 102 (96%); among these women, 87 (85%) were screened for HBsAg upon admission for delivery. The odds of receiving HBsAg screening among women who received prenatal care was significantly higher than among those who did not receive prenatal care (odds ratio = 8.82, p<0.001).
Among 899 women with available HBsAg screening result data, 18 (2%) were HBsAg-positive, of whom 14 were Pacific Islanders and four were Asian. Sixteen (89%) HBsAg-positive women were aged >25 years of age at delivery (born before the introduction of hepatitis B vaccine into the routine immunization program in 1988), and were therefore less likely to have been vaccinated against hepatitis B as infants; hepatitis B vaccination status of mothers was not available. All 18 infants born to HBsAg-positive women received hepatitis B vaccination within 12 hours of delivery and 17 of 18 received HBIG.
Discussion
The prevalence of prenatal HBsAg screening in this hospital-based random sample of women with a live birth during 2014 in Guam (97%) was similar to the 94% prevalence estimate in the continental United States in 2010 (7); however, the 2.0% HBsAg positivity prevalence in this sample is approximately 13 times higher than the 0.14% maternal prevalence estimate among U.S.-born Pacific Islander and Asian women and approximately twice the 0.9% maternal prevalence estimate in the continental United States (7,8). Despite the high HBsAg prevalence in this sample, all infants born to HBsAg-positive women received hepatitis B vaccine, and all but one infant received HBIG. Most of the HBsAg-positive women included in the sample were born before hepatitis B vaccine was introduced into Guam’s universal infant vaccination schedule; although catch-up vaccination programs were implemented in later years, many women might have been missed. However, infant and childhood hepatitis B vaccination coverage has significantly increased in Guam and the other U.S-affiliated Pacific Islands since the introduction of universal infant hepatitis B vaccination (9). The estimated hepatitis B vaccine coverage among children in this region is 98%; consequently, the risk for perinatal HBV transmission is likely to decrease in future birth cohorts (9).
The findings in this report are subject to at least two limitations. First, although this hospital accounted for approximately three quarters of births registered in 2014 in Guam, the data came from only one hospital; therefore, the prevalence of prenatal HBsAg screening, maternal HBsAg positivity, hepatitis B vaccination, and HBIG administration cannot be generalized to all health care facilities in Guam. Second, no postvaccination serologic testing data for the 18 infants born to HBsAg-positive mothers were available to assess HBV infection and immune response status, although administration of hepatitis B vaccine and HBIG within 12 hours of birth is reported to be 85%–95% effective in preventing perinatal transmission (5).
The prevalence of HBsAg screening among women who had at least one prenatal care visit (98%) was significantly higher than that among women who did not (85%). Prenatal screening of all pregnant women for HBsAg is a critical component of the HBV elimination strategy in the United States and its territories (6), especially in areas with a high prevalence of HBV infection in adults. Prenatal screening facilitates the timely identification of HBsAg-positive women and ensures that PEP is available to their infants immediately after delivery, thus reducing the likelihood of infants becoming chronically infected and serving as reservoirs for continued HBV transmission (5,10). Prenatal care is important for prenatal HBSAg screening in Guam. Fully implementing systemic and institutional hospital policies that require documentation of maternal HBsAg status in hospital maternity records and the administration of PEP to all infants of HBsAg-positive mothers will ensure that all infants at risk receive PEP and that the risk for perinatal HBV transmission is reduced (7).
Corresponding author: Winston Abara, wabara@cdc.gov, 404-639-8132.
1Epidemic Intelligence Service, CDC; 2Division of Viral Hepatitis, CDC; 3Division of Sexually Transmitted Diseases Prevention, CDC; 4Division of Scientific Education and Professional Development, CDC; 5Emory University School of Medicine, Atlanta, Georgia; 6Guam Department of Public Health and Social Services; 7Guam Memorial Hospital Authority.
References
- Haddock RL, Paulino YC, Bordallo R. Viral hepatitis and liver cancer on the island of Guam. Asian Pac J Cancer Prev 2013;14:3175–6. CrossRef PubMed
- Hennessey K, Mendoza-Aldana J, Bayutas B, Lorenzo-Mariano KM, Diorditsa S. Hepatitis B control in the World Health Organization’s Western Pacific Region: targets, strategies, status. Vaccine 2013;31(Suppl 9):J85–92. CrossRef PubMed
- Nelson NP, Easterbrook PJ, McMahon BJ. Epidemiology of hepatitis B virus infection and impact of vaccination on disease. Clin Liver Dis 2016;20:607–28. CrossRef PubMed
- Edmunds WJ, Medley GF, Nokes DJ, Hall AJ, Whittle HC. The influence of age on the development of the hepatitis B carrier state. Proc Biol Sci 1993;253:197–201. CrossRef PubMed
- Beasley RP, Hwang LY, Lee GC, et al. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet 1983;2:1099–102. CrossRef PubMed
- CDC. Prevention of perinatal transmission of hepatitis B virus: prenatal screening of all pregnant women for hepatitis B surface antigen. MMWR Morb Mortal Wkly Rep 1988;37:341–6. PubMed
- Willis BC, Wortley P, Wang SA, Jacques-Carroll L, Zhang F. Gaps in hospital policies and practices to prevent perinatal transmission of hepatitis B virus. Pediatrics 2010;125:704–11. CrossRef PubMed
- Smith EA, Jacques-Carroll L, Walker TY, Sirotkin B, Murphy TV. The national perinatal hepatitis B prevention program, 1994–2008. Pediatrics 2012;129:609–16. CrossRef PubMed
- Abara WE, Collier MG, Teshale EH. Impact of universal infant hepatitis B vaccination in the US-affiliated Pacific Islands, 1985–2015. Vaccine 2017;35:997–1000. CrossRef PubMed
- Mast EE, Margolis HS, Fiore AE, et al. ; Advisory Committee on Immunization Practices. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep 2005;54(No. RR-16). PubMed
TABLE. Demographic characteristics, prenatal hepatitis B surface antigen (HBsAg) screening, prenatal care received, and screening results among a random sample of pregnant women with live-born deliveries, and receipt of hepatitis B virus postexposure prophylaxis among infants of HBsAg-positive mothers — Guam Memorial Hospital, Guam, 2014 (N = 966)
| Characteristic | No. (%)* |
|---|---|
| Race/Ethnicity (N = 962) | |
| Pacific Islander | 752 (78.2) |
| Asian | 197 (20.5) |
| White | 11 (1.1) |
| Hispanic | 2 (0.2) |
| Prenatal HBsAg screening received† (N = 936) | |
| Yes | 905 (96.7) |
| No | 31 (3.3) |
| Prenatal care received§ (N = 963) | |
| Yes | 857 (89.0) |
| No | 106 (11.0) |
| Prenatal HBsAg screening among women with prenatal care (N = 834) | |
| Yes | 818 (98.1) |
| No | 16 (1.9) |
| Prenatal HBsAg screening among women without prenatal care (N = 102) | |
| Yes | 87 (85.3) |
| No | 15 (14.7) |
| Maternal HBsAg screening results (N = 899) | |
| HBsAg-positive | 18 (2.0) |
| HBsAg-negative | 881 (98.0) |
| Receipt of postexposure HBV prophylaxis among infants born to HBsAg-positive women¶ (N = 18) | |
| Received HB vaccine within 12 hrs of delivery | 18 (100) |
| Received HBIG within 12 hrs of delivery | 17 (94) |
| Age at delivery, yrs (N = 966) | |
| Mean | 27.2 |
| Median | 27.0 |
| Range (SD) | 15–45 (6.2) |
| >25 yrs (all mothers [N = 966]) | 542 (56.1) |
| >25 yrs (HBsAg-positive mothers [N = 18]) | 16 (88.9) |
Abbreviations: HBIG = hepatitis B immune globulin; HBV = hepatitis B virus; SD = standard deviation.
* Except as noted.
† Includes women screened during prenatal care and women without prenatal care who were screened upon admission for delivery.
§ At least one prenatal care visit before delivery.
¶ Limited to infants born to HBsAg-positive mothers.
Suggested citation for this article: Abara WE, Cha S, Malik T, et al. Hepatitis B Surface Antigen Screening Among Pregnant Women and Care of Infants of Hepatitis B Surface Antigen–Positive Mothers — Guam, 2014. MMWR Morb Mortal Wkly Rep 2017;66:506–508. DOI: http://dx.doi.org/10.15585/mmwr.mm6619a5.
MMWR and Morbidity and Mortality Weekly Report are service marks of the U.S. Department of Health and Human Services.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of
Health and Human Services.
References to non-CDC sites on the Internet are
provided as a service to MMWR readers and do not constitute or imply
endorsement of these organizations or their programs by CDC or the U.S.
Department of Health and Human Services. CDC is not responsible for the content
of pages found at these sites. URL addresses listed in MMWR were current as of
the date of publication.
All HTML versions of MMWR articles are generated from final proofs through an automated process. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version (https://www.cdc.gov/mmwr) and/or the original MMWR paper copy for printable versions of official text, figures, and tables.
Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.